Search Result

Results for "

DRGs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (1) Adenosine Receptor (1) Angiotensin Receptor (2) Apoptosis (1) Autophagy (1) Calcium Channel (2) DNA Alkylator/Crosslinker (1) Endogenous Metabolite (1) HBV (1) Mas-related G-protein-coupled Receptor (MRGPR) (1) Microtubule/Tubulin (1) Opioid Receptor (1) PKA (1) Potassium Channel (2) Prostaglandin Receptor (1) Small Interfering RNA (siRNA) (2) Sodium Channel (8) TRP Channel (4)
By Research Areas:	Cancer (4) Cardiovascular Disease (3) Endocrinology (2) Infection (2) Inflammation/Immunology (3) Neurological Disease (20)
Oligonucleotides:	Pre-designed siRNA Sets (2) siRNAs (2)

Inhibitors & Agonists

Peptides

Natural
Products

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6789

KT5720 3 Publications Verification	PKA	Neurological Disease Cancer
KT5720 is a potent, cell-permeable, specific, reversible and ATP-competitive PKA inhibitor (IC₅₀=3.3 μM). KT5720 is effective in reversing MDR1-mediated multidrug resistance. KT5720 also reduces the excitability of dorsal root ganglion (DRG) neurons by attenuating Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel activity and reducing intracellular Ca2 ⁺ concentrations. KT5720 can be used in the study of haematological malignancies as well as HCN and DRG neuron-related diseases .

HY-157802

LTGO-33	Sodium Channel	Neurological Disease
LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .

HY-13106

Olodanrigan 1 Publications Verification EMA401; PD-126055; (S)-EMA400	Angiotensin Receptor	Neurological Disease Endocrinology
Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-161327

HBV-IN-44	HBV	Infection
HBV-IN-44 (Compound (S)-2a) is a HBV inhibitor with a IC₅₀ value of 23 nM for HbsAg. HBV-IN-44 is less toxic to the neurite growth of HT22 cells and DRG neurons in vitro .

HY-P5756

CSD-CH2(1,8)-NH2	Opioid Receptor	Neurological Disease
CSD-CH2(1,8)-NH2 is a selective and competitive KOR antagonist (K_i: 6.8 nM). CSD-CH2(1,8)-NH2 inhibits calcium mobilization in DRG neurons. CH2(1,8)-NH2 antagonizes the antinociceptive effect of U50,488. CSD-CH2(1,8)-NH2 can be used for research of neuropsychiatric disorders .

HY-P10358

TAT-CBD3A6K	Calcium Channel	Neurological Disease
TAT-CBD3A6K, is a modified TAT-CBD3 peptide. TAT-CBD3A6K reduces T- and R-type voltage-dependent calcium currents in dorsal root ganglion (DRG) neurons. TAT-CBD3A6K shows anti-nociceptive effects in a model of AIDS-induced peripheral neuropathy by preventing CRMP-2-mediated enhancement of T- and R-type calcium channel function .

HY-RS04009

DRG1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DRG1 Human Pre-designed siRNA Set A contains three designed siRNAs for DRG1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DRG1 Human Pre-designed siRNA Set A DRG1 Human Pre-designed siRNA Set A

HY-RS04010

DRG2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
DRG2 Human Pre-designed siRNA Set A contains three designed siRNAs for DRG2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

DRG2 Human Pre-designed siRNA Set A DRG2 Human Pre-designed siRNA Set A

HY-13106A

Olodanrigan sodium EMA401 sodium; PD-126055 sodium	Angiotensin Receptor	Neurological Disease Endocrinology
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-116704

11-Deoxyprostaglandin F2α	Potassium Channel	Neurological Disease
11-Deoxyprostaglandin F2α is an activator for TREK-2 channels with EC₅₀ of 0.294 μM. 11-Deoxyprostaglandin F2α inhibits the K2P channel TREK-1 .

HY-101160

SG2057 DRG16	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
SG2057 (DRG16) is a PBD dimer containing a pentyldioxy linkage which binds sequence selectively in the minor groove of DNA forming DNA interstrand and intrastrand cross-linked adducts. SG2057 is a highly active antitumor agent .

HY-118941

BAY 73-1449	Prostaglandin Receptor	Cardiovascular Disease
BAY 73-1449 is a selective antagonist of prostacyclin receptor (IP), with high potency (IC₅₀ of less than 0.1 nM) in cAMP assays in Human HEL cells and rat DRG. BAY 73-1449 can be used in the research of lowering blood pressure .

HY-N2500

Deoxypodophyllotoxin	Microtubule/Tubulin Apoptosis Autophagy	Infection Cardiovascular Disease
Deoxypodophyllotoxin (DPT), a derivative of podophyllotoxin, is a lignan with potent antimitotic, anti-inflammatory and antiviral properties isolated from Anthriscus sylvestris. Deoxypodophyllotoxin, targets the microtubule, has a major impact in oncology not only as anti-mitotics but also as potent inhibitors of angiogenesis . Deoxypodophyllotoxin induces cell autophagy and apoptosis . Deoxypodophyllotoxin evokes increase of intracellular Ca ²⁺ concentrations in DRG neurons .

HY-108425

AMG8379	Sodium Channel	Neurological Disease
AMG8379 is a potent, orally active and selective sulfonamide antagonist of the voltage-gated sodium channel NaV1.7, with IC₅₀s of 8.5 and 18.6 nM for hNaV1.7 and mNaV1.7, respectively. AMG8379 potently and reversibly blocks endogenous Tetrodotoxin (TTX)-sensitive sodium channels in dorsal root ganglia (DRG) neurons with an IC₅₀ of 3.1 nM .

HY-12914

V116517	TRP Channel	Neurological Disease Inflammation/Immunology
V116517 is a potent, orally active transient receptor potential vanilloid (TRPV1) antagonist. V116517 shows potent activity in inhibiting both capsaicin (CAP)- and acid (pH 5)-induced currents in rat DRG neurons expressing native TRPV (IC₅₀=423.2 nM for CAP; IC₅₀=180.3 nM for acid). V116517 can be used for the research of pain .

HY-110285

ML382	Mas-related G-protein-coupled Receptor (MRGPR)	Neurological Disease
ML382 is a potent and selective MRGPRX1 (Mas-related G protein-coupled receptor X1, MrgX1) positive allosteric modulator, with an EC₅₀ of 190 nM .

HY-121119

MRS 1523 2 Publications Verification	Adenosine Receptor Calcium Channel	Cardiovascular Disease Neurological Disease Inflammation/Immunology
MRS 1523 is a potent and selective adenosine A₃ receptor antagonist with K_i values of 18.9 nM and 113 nM for human and rat A₃ receptors, respectively. In rat this corresponds to selectivities of 140- and 18-fold vs A₁ and A_2A receptors, respectively. MRS 1523 can exert antihyperalgesic effect through N-type Ca channel block and action potential inhibition in isolated rat dorsal root ganglion (DRG) neurons .

HY-157802A

(S)-LTGO-33	Sodium Channel	Neurological Disease
(S)-LTGO-33 is a small molecule inhibitor of voltage-gated sodium channel NaV1.8. (S)-LTGO-33 can be used in the treatment of pain disorders .

HY-N6825

Hydroxy-α-sanshool 3 Publications Verification	TRP Channel Endogenous Metabolite	Neurological Disease
Hydroxy-α-sanshool is a transient receptor potential ankyrin 1 (TRPA1) and TRP vanilloid 1 (TRPV1) agonist with EC₅₀s of 69 and 1.1 μM, respectively. Hydroxy-α-sanshool can be used for pain research .

HY-P5868

mHuwentoxin-IV	Sodium Channel	Neurological Disease
mHuwentoxin-IV is a naturally modified Huwentoxin-IV (HY-P1220). mHuwentoxin-IV inhibits tetrodotoxin-sensitive (TTX-S) voltage-gated sodium channels of dorsal root ganglion neurons with an IC₅₀ of 54.16 nM. mHuwentoxin-IV inhibition of tetrodotoxin-sensitive sodium channels is not reversed by strong depolarization voltages .

HY-162347

Nav1.7-IN-13	Sodium Channel	Neurological Disease
Nav1.7-IN-13 (compound 3g) is a sodium channel inhibitor that significantly inhibits Veratridine (HY-N6691)-induced neuronal activity. Nav1.7-IN-13 inhibits total Na+ current in DRG neurons in a concentration-dependent manner; slows down the activation of Navs. Nav1.7-IN-13 significantly alleviated mechanical pain behavior in a rat model of nerve injury (SNI) and had analgesic activity .

HY-N6691

Veratridine 2 Publications Verification 3-Veratroylveracevine	Sodium Channel	Neurological Disease
Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC₅₀ of 18.39 µM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .

HY-N6691R

Veratridine (Standard)	Sodium Channel	Neurological Disease
Veratridine (Standard) is the analytical standard of Veratridine. This product is intended for research and analytical applications. Veratridine (3-Veratroylveracevine) is a plant neurotoxin, a voltage-gated sodium channels (VGSCs) agonist. Veratridine inhibits the peak current of Nav1.7, with an IC₅₀ of 18.39?μM. Veratridine regulates sodium ion channels mainly by activating sodium ion channels, preventing channel inactivation and increasing sodium ion flow .

HY-108576

Linopirdine dihydrochloride DuP 996 dihydrochloride	TRP Channel	Neurological Disease
Linopirdine dihydrochloride is a agonist of capsaicin receptor TRPV1. Linopirdine increases the intracellular calcium concentration in HEK293 cells. Linopirdine dihydrochloride exerts an excitatory action on mammalian nociceptors .

HY-108449

Acoltremon 1 Publications Verification WS-12; AR-15512; AVX-012	TRP Channel	Cancer
Acoltremon (WS-12; AR-15512) is a potent and selective TRPM8 agonist, the menthol derivative, as a cooling agent. Acoltremon shows analgesic effect, and can be used in chronic neuropathic pain research .

HY-110150

UNC3230 Maximum Cited Publications 6 Publications Verification	Others	Inflammation/Immunology Cancer
UNC3230 is a potent, selective and ATP-competitive PIP5K1C inhibitor with an IC₅₀ of ~41 nM. UNC3230 also inhibits PIP4K2C and does not inhibit any of the other lipid kinases that regulate phosphoinositide levels. UNC3230 has antinociceptive and anticancer effects .

HY-P5782

δ-Theraphotoxin-Hm1a toxin	Sodium Channel	Neurological Disease
δ-Theraphotoxin-Hm1a toxin is a selective Na_v1.1 activator. δ-Theraphotoxin-Hm1a toxin elicits pain and touch sensitivity. δ-Theraphotoxin-Hm1a toxin can be used for the research of irritable bowel syndrome .

HY-W013712

GI-530159	Potassium Channel	Neurological Disease
GI-530159 is a selective opener of TREK1 and TREK2 potassium channels. GI-530159 displays selectivity for TREK1/2 over TRAAK, TASK3 and other potassium channels, with an EC₅₀ of 0.76 μM for TREK1. GI-530159 reduces rat dorsal root ganglion neuron excitability and shows potential analgesic effect .

Cat. No.	Product Name	Target	Research Area